<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9961">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686551</url>
  </required_header>
  <id_info>
    <org_study_id>BN42489</org_study_id>
    <secondary_id>Other</secondary_id>
    <nct_id>NCT05686551</nct_id>
  </id_info>
  <brief_title>GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with&#xD;
      placebo in participants with prodromal and early manifest Huntington's Disease&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2023</start_date>
  <completion_date type="Anticipated">January 4, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 3, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events, with severity determined according to the Adverse Event Severity Grading Scale</measure>
    <time_frame>Up to Approximately 24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory results - Cerebrospinal fluid (CSF) White Blood Cell (WBC) (1/uL)</measure>
    <time_frame>From Baseline Visit (Day 1), and Months 4, 8, 9, 12, 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory results Cerebrospinal fluid (CSF) protein (g/L)</measure>
    <time_frame>From Baseline Visit (Day 1), and Months 4, 8, 9, 12, 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in baseline in structural MRI assessing any new abnormalities including radiographic features consistent with hydrocephalus and other relevant MRI safety findings</measure>
    <time_frame>From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage change from baseline in geometric means of CSF mHTT protein levels at Month 9</measure>
    <time_frame>Baseline and Month 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) Scores (non-U.S. sites) at 16 months</measure>
    <time_frame>Up to Approximately 16 Months</time_frame>
    <description>Change in scores on the scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Total Functional Capacity (TFC) Scores (U.S. sites) at 16 months</measure>
    <time_frame>Baseline and 16 Months</time_frame>
    <description>Change in scores on the scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MoCA Scores</measure>
    <time_frame>From Baseline, Months 4, 8, 12, 16 and up to approximately Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with suicidal ideation or behavior as assessed by C-SSRS score at each visit, including detailed focus on any individual cases identified as having severe ideation or behavior during the study conduct</measure>
    <time_frame>Up to Approximately 24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 16 months for the assessments of TFC (non-U.S. sites) Scores</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 16 months for the assessments of cUHDRS (U.S. sites) Scores</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 16 months for the assessments of Symbol Digit Modalities Test (SDMT) Scores</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline at 16 Months for the Assessments of Stroop Word Reading (SWR) Scores</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 16 months for the assessments of Total Motor Score (TMS)</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CSF Neurofilament light Chain (NfL) levels at 16 months</measure>
    <time_frame>Baseline to 16 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADAs) at specified timepoints relative to the prevalence of ADAs at baseline</measure>
    <time_frame>From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers determined if ADAs are identified</measure>
    <time_frame>From Baseline, Months 4, 8, 12, 16 and Up to Approximately Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Tominersen 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tominersen 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tominersen 60 mg</intervention_name>
    <description>60 mg tominersen administered intrathecally every 16 weeks</description>
    <arm_group_label>Tominersen 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered intrathecally every 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tominersen 100 mg</intervention_name>
    <description>100 mg tominersen administered intrathecally every 16 weeks</description>
    <arm_group_label>Tominersen 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          -  Signed study companion consent form. A study companion is required for all&#xD;
             participants.&#xD;
&#xD;
          -  HD gene expansion mutation carrier status. CAP score of 400-500, inclusive, where CAP&#xD;
             is calculated as follows:&#xD;
&#xD;
        Age x (CAG repeat length -33.66)&#xD;
&#xD;
        -Prodromal HD, defined as DCL 2 to 3, Total Motor Score (TMS) &gt;6, Independence Scale (IS) =&#xD;
        100 (broadly equivalent to HD-ISS Stage 2), or early manifest HD, defined as DCL 4, TMS &gt;&#xD;
        6, 100 &gt;IS&gt;/= 70, and TFC &gt;/=8 (broadly equivalent to HD-ISS Stage 3)&#xD;
&#xD;
        Companion Inclusion Criteria&#xD;
&#xD;
        - HD gene expansion mutation carrier status. CAP score of 400-500, inclusive, where CAP is&#xD;
        calculated as follows: Age x (CAG repeat length -33.66)&#xD;
&#xD;
          -  Prodromal HD, defined as DCL 2 to 3, Total Motor Score (TMS) &gt;6, Independence Scale&#xD;
             (IS) = 100 (broadly equivalent to HD-ISS Stage 2), or early manifest HD, defined as&#xD;
             DCL 4, TMS &gt; 6, 100 &gt;IS&gt;/= 70, and TFC &gt;/=8 (broadly equivalent to HD-ISS Stage 3)&#xD;
&#xD;
          -  Signed study companion consent form. A study companion is required for all&#xD;
             participants.&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
          -  Current or previous use of an ASO (including small interfering RNA) or any HTT&#xD;
             lowering therapy (including tominersen)&#xD;
&#xD;
          -  Anti-platelet or anticoagulant therapy within 14 days prior to screening or&#xD;
             anticipated use during the study, including, but not limited to, aspirin (unless &lt;/=&#xD;
             81 mg/day), clopidogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, apixaban,&#xD;
             and heparin&#xD;
&#xD;
          -  History of gene therapy, cell transplantation, or brain surgery&#xD;
&#xD;
          -  Hydrocephalus&#xD;
&#xD;
          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the study or&#xD;
             within 5 months after the final dose of study drug&#xD;
&#xD;
          -  History of attempted suicide or suicidal ideation with plan (i.e., active suicidal&#xD;
             ideation) that required hospital visit and/or change in level of care within 12 months&#xD;
             prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reference Study ID Number: BN42489 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uab Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CenExel Rocky Mountain Clinical Research, LLC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CINME</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>INEBA</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1192AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Perron Institute for Neurological and Translational Science</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Hukommelsesklinikken</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Abteilung Molekulare Neurologie</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta; U.O.C. Genetica Medica-Neurogenetica</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Sw. Wojciecha; Oddzial Neurologiczny</name>
      <address>
        <city>Gda?sk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K</name>
      <address>
        <city>Krakow</city>
        <zip>31-505</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Psychiatrii i Neurologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces; Servicio de Neurologia</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Badajoz; Servicio de Neurología</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos. Servicio de Neurología</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Neurologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurozentrum Siloah</name>
      <address>
        <city>Gümligen</city>
        <zip>3073</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCL Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>December 16, 2022</study_first_submitted>
  <study_first_submitted_qc>January 6, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>May 12, 2023</last_update_submitted>
  <last_update_submitted_qc>May 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prodromal and Early Manifest Huntington's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

